Ascendis Pharma A/S ASND.OQ, ASND.O is expected to show a fall in quarterly revenue when it reports results on February 5 (estimated) for the period ending December 31 2024
The Hellerup Denmark-based company is expected to report a 19.3% decrease in revenue to €111.178 million from €137.7 million a year ago, according to the mean estimate from 12 analysts, based on LSEG data.
LSEG's mean analyst estimate for Ascendis Pharma A/S is for a loss of €1.14 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Ascendis Pharma A/S is $196.00, above its last closing price of $130.66.
Previous quarterly performance (using preferred earnings measure in euros).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -1.76 | -1.74 | -1.72 | Beat | 1.2 |
Jun. 30 2024 | -1.34 | -1.38 | -1.91 | Missed | -38.1 |
Mar. 31 2024 | -1.46 | -1.50 | -2.30 | Missed | -53.1 |
Dec. 31 2023 | -1.98 | -2.03 | -1.54 | Beat | 24 |
Sep. 30 2023 | -2.32 | -2.38 | -2.88 | Missed | -21.1 |
Jun. 30 2023 | -2.57 | -2.59 | -2.16 | Beat | 16.6 |
Mar. 31 2023 | -2.65 | -2.66 | -1.98 | Beat | 25.6 |
Dec. 31 2022 | -2.44 | -2.56 | -3.70 | Missed | -44.5 |
This summary was machine generated February 3 at 12:21 GMT. All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.